Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response
- 26 May 2008
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 200 (2) , 177-186
- https://doi.org/10.1007/s00213-008-1193-9
Abstract
A number of human and animal studies implicate GSK3 in the pathophysiology and genetics of schizophrenia. In general, the data suggest that phosphorylation levels of GSK3β are reduced in schizophrenia, resulting in increased GSK3β activity. Since GSK3β regulation is altered in schizophrenia, polymorphic variation in this gene may affect susceptibility to schizophrenia or treatment response.Keywords
This publication has 66 references indexed in Scilit:
- Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortexExperimental & Molecular Medicine, 2007
- A tutorial on statistical methods for population association studiesNature Reviews Genetics, 2006
- Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and TherapeuticsNeurochemical Research, 2006
- An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and BehaviorCell, 2005
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Pedigree disequilibrium tests for multilocus haplotypesGenetic Epidemiology, 2003
- Glycogen synthase kinase (GSK)-3β levels and activity in a neurodevelopmental rat model of schizophreniaDevelopmental Brain Research, 2003
- Trimming, Weighting, and Grouping SNPs in Human Case-Control Association StudiesGenome Research, 2001
- Glycogen synthase kinase-3β immunoreactivity is reduced in the prefrontal cortex in schizophreniaNeuroscience Letters, 2001
- Detecting Marker-Disease Association by Testing for Hardy-Weinberg Disequilibrium at a Marker LocusAmerican Journal of Human Genetics, 1998